Novartis AG

Novartis AG is a declared insider at 2 companies; the most frequent names are Idenix Pharmaceuticals Inc and Alnylam Pharmaceuticals, Inc. Between 4 April 2006 and 20 September 2012, the trades on record add up to 63 filings.

Both buying and selling appear: 62 purchases worth €9.3M, against 1 sale worth €23.2M. Netting one side against the other leaves €13.9M of net selling. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Since January 2012: 19 purchases and 1 sale on the market.

A typical purchase (the median) is worth €5,022. For 3 purchases whose 90-day window has closed, the share price was higher on day 90 than the day after publication in 67% of cases, with a median move of +11.3%. They describe history only and say nothing certain about the share price ahead.

Most recently, on 24 September 2012, the filings show an open-market sale worth €23.2M in Alnylam Pharmaceuticals, Inc. The last purchase on record was published on 23 February 2012, which is 5,356 days ago. The median gap between trade and publication is zero days: most filings appear on the same day. US insiders must file a Form 4 within two business days of a trade. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.